SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCOctober 2, 2026

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

Patients with advanced non-small cell lung cancer (NSCLC) whose tumours carried a high tumour mutational burden developed immune-related adverse events more often and sooner on checkpoint inhibitors, according to a brief report by Federica Pecci, Biagio Ricciuti and colleagues in the Journal of Thoracic Oncology.
Share

In brief

  • In a single-centre cohort of 1215 patients with advanced NSCLC treated with immune checkpoint inhibitors, 421 (34.7%) developed an immune-related adverse event.
  • Higher baseline tumour mutational burden (TMB) was associated with a higher risk of an immune-related adverse event (adjusted odds ratio 1.04, p < 0.001) and with earlier onset (adjusted hazard ratio 1.02, p = 0.002).
  • A TMB at or above the cohort’s 90th percentile, 19 mutations per megabase, was the strongest predictor: adjusted odds ratio 2.14 (p < 0.001) and adjusted hazard ratio 1.58 for earlier onset (p = 0.004).
  • The association persisted in adjusted landmark analyses at 6, 9 and 12 weeks, and the authors conclude that it is independent of longer immunotherapy exposure.
  • Tumours with TMB at or above 19 mutations per megabase contained more CD8+ cells (p = 0.04).

Study at a glance

  • Cohort: Single-centre cohort study
  • Population: 1215 patients with advanced NSCLC and TMB measured by OncoPanel next-generation sequencing
  • Treatment: Immune checkpoint inhibitors alone (63.4%) or with chemotherapy; 61.4% treated in the first line
  • Outcome measured: Occurrence and time to onset of immune-related adverse events
  • Events: 421 patients (34.7%) developed an immune-related adverse event
  • Highest-TMB group: TMB of 19 mutations per megabase or more (90th percentile); adjusted odds ratio 2.14, adjusted hazard ratio 1.58
  • Tissue analysis: Multiplex immunofluorescence for CD8+, PD-1+, CD8+PD-1+ and FOXP3+ cells
  • Not reported: The grade and organ distribution of the adverse events, the number of patients in the highest-TMB group, and any efficacy or survival outcomes

About one in three patients developed immune-related toxicity

The cohort included patients with advanced NSCLC who received checkpoint inhibitors with or without chemotherapy and whose baseline TMB had been measured with the OncoPanel sequencing assay. Of the 1215 patients, 63.4% received a checkpoint inhibitor alone and 61.4% were treated in the first-line setting.

A total of 421 patients developed an immune-related adverse event. The authors related baseline TMB to these events with two models: logistic regression for whether an event occurred, and Cox proportional hazards regression for how soon it occurred.

A TMB at or above 19 mutations per megabase more than doubled the adjusted odds

Across the cohort, higher baseline TMB carried an adjusted odds ratio of 1.04 for developing an immune-related adverse event (p < 0.001) and an adjusted hazard ratio of 1.02 for earlier onset (p = 0.002).

The authors then compared patients at or above the 90th percentile of TMB, which corresponded to 19 mutations per megabase, with the remaining 90%. The highest-TMB group had an adjusted odds ratio of 2.14 for an immune-related adverse event (p < 0.001) and an adjusted hazard ratio of 1.58 for earlier onset (p = 0.004). The authors report this threshold as the strongest predictor of both outcomes.

Landmark analyses at 6, 9 and 12 weeks addressed treatment duration

TMB is an established predictor of response to checkpoint inhibitors in advanced NSCLC, and patients who respond remain on treatment longer. A raw association between TMB and adverse events could therefore reflect longer exposure alone. The authors report 6-, 9- and 12-week landmark analyses, and conclude that the association is independent of longer immunotherapy exposure.

After adjustment for age, sex, Eastern Cooperative Oncology Group performance status, PD-L1 expression and treatment type, a TMB of 19 mutations per megabase or more remained associated with a higher risk of an immune-related adverse event at each of the three landmarks.

“These findings indicate that a high TMB, particularly TMB more than or equal to the 19 mut/Mb, is associated with an increased risk and earlier irAE onset, independent of longer immunotherapy exposure.”Pecci et al., Journal of Thoracic Oncology (2026)

More CD8+ cells in the highest-TMB tumours

To look for a biological explanation, the investigators measured the density of CD8+, PD-1+, CD8+PD-1+ and FOXP3+ immune cells in tumour tissue with multiplex immunofluorescence. Tumours with TMB of 19 mutations per megabase or more were enriched for CD8+ cells compared with tumours below that threshold (p = 0.04).

The authors interpret this as a sign that the association is biologically driven, and they propose elevated TMB as a biomarker for immune-related adverse events. The abstract does not state whether the other three cell populations differed between the groups.

A threshold drawn from one centre’s own distribution

The 19 mutations per megabase cut-off is the 90th percentile of this cohort, measured on one sequencing panel, OncoPanel, at one institution. The abstract does not say whether the same number identifies the same patients on another assay or in another cohort.

The design is observational. Patients were not assigned to treatment by TMB, and adjusted estimates can correct only for the variables that were measured; for the landmark analyses these were age, sex, performance status, PD-L1 expression and treatment type.

Sources

  1. Journal of Thoracic Oncology. Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report (2026-08-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Biagio Ricciuti.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Nov 13 2026
ILCS 2026
Biomarkers

ctDNA-guided decisions in lung cancer: ready or not?

M. Das
Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nov 16 2026
RESEARCH
Immunotherapies

Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma

J. RemonN. GirardN. Reguart
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle